Metabolic bariatric surgery markedly enhances glycemic control and liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH). A scoping review of 14 studies reveals substantial reductions in fasting glucose, insulin resistance, and liver enzymes, alongside histological improvements, including decreased steatosis and fibrosis. These changes, observed over follow-up periods of 6 months to 5 years, underline the procedure’s potential as a key treatment strategy for addressing MASH effectively and improving metabolic health.
Review by Shah A, Mohammadi A (…) Zevin B et 2 al. in Obes Surg
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.